SEQSTER and CLEAR Forge Partnership
SEQSTER has launched a partnership with CLEAR to provide patients with Individual Access Services and allow them to securely access, control, and share their personal health information with authorized users. SEQSTER has integrated the CLEAR platform to allow patients to confirm their identity, access their medical records, and safely share them with various clinical trial research organizations within the SEQSTER Operating System for healthcare.
With this partnership, patients can now affirm their identity—with a government-issued ID and a selfie—to create and manage their SEQSTER account. Once a SEQSTER patient verifies their identity and creates their account, they can securely share their personal health information with SEQSTER’s life sciences partners.
Reference
SEQSTER and CLEAR Forge Partnership to Drive Innovation and Improve Patient Outcomes with Real-World Data. (2023, April 17). EIN Presswire.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
